The global HIV drugs market size was estimated to be USD 34.26 billion in 2023 and is expected to reach at USD 64.83 billion by 2034 with a CAGR of 5.97% during the forecast period 2024-2034. The surge in the demand for HIV medications, escalating initiatives from diverse government entities to promote awareness regarding the diagnosis and management of HIV, an increase in HIV cases, heightened awareness about HIV driving more individuals toward testing and diagnosis, an upswing in funding from international programs and organizations aimed at raising awareness and alleviating the burden of HIV, and a growing investment in research and development endeavors to enhance comprehension of HIV's underlying mechanisms & devise innovative therapies, and the upsurge in research and development activities in drug discovery are some of the key factors boosting the market growth.
The upsurge in research and development activities in drug discovery is predicted to boost the market growth during the forecast period. This involves the exploration of novel drug targets, the undertaking of clinical trials, and the examination of combination therapies. For instance, in February 2023, Merck, also recognized as MSD outside the United States and Canada, has declared the initiation of enrollment in its latest Phase 3 clinical initiative. This program involves the investigation of the investigational once-daily islatravir 0.25 mg in conjunction with doravirine 100 mg (DOR/ISL) for treating HIV-1 infection.
By medication class, multi-class combination drugs was the highest revenue-grossing segment in the global HIV drugs market in 2023 owing to the widespread utilization of combination drugs encompassing multiple classes in HIV treatment, the efficacy of these multi-class combinations against HIV, and the increasing endorsement of such combination drugs. For instance, in December 2022, Gilead Sciences, Inc. reported that the U.S. Food and Drug Administration (FDA) has approved Sunlenca (lenacapavir) in combination with other antiretroviral(s) (ARV) for treating HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. Additionally, HIV integrase strand transfer inhibitors is predicted to grow at fastest CAGR during the forecast period as it is recommended as primary treatment for HIV and the continuous introduction of new drugs, this combination represents a significant advancement in HIV therapy.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global HIV drugs market in 2023 owing to the substantial drug sales originating from hospital pharmacies, the elevated count of HIV patients seeking treatment at hospital facilities, and surge in market approvals by regulatory bodies. For instance, in February 2023, ViiV Healthcare, a subsidiary of GlaxoSmithKline plc, declared that the European Commission has approved Marketing Authorization for Triumeq. This approval pertains to a dispersible tablet version of the fixed-dose combination of abacavir, dolutegravir, and lamivudine, designed for treating pediatric patients weighing between 14 kg to 25 kg with human immunodeficiency virus type 1 (HIV-1). Additionally, online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the ease of shopping, growth in online sales, advancements in logistics, and simplified payment choices contribute to the accessibility and substantial discounts and offers offered by these digital platforms.
North America region is anticipated for the highest revenue share during the forecast period owing to the increase in the quantity of clinical trials for HIV medications, the presence of advanced healthcare facilities, substantial healthcare funding from governmental entities, the presence of an intricate reimbursement system designed to lower expenditure, and the rising number of approvals from regulatory bodies. For instance, in March 2022, Janssen Pharmaceutical, a fully owned subsidiary of Johnson & Johnson, reported that the U.S. Food and Drug Administration (FDA) granted approval for CABENUVA (cabotegravir and rilpivirine) to treat HIV-1 in adolescents who have achieved virological suppression. Developed in collaboration with ViiV Healthcare, CABENUVA stands as the initial and sole comprehensive long-acting treatment regimen for HIV-1. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the existence of major contributors, an upswing in research and development endeavors focused on HIV medications, an increase in the demand for HIV drugs, a growing population coupled with extended life expectancy, and an uptick in regulatory approvals for innovative products. For instance, in May 2022, ViiV Healthcare, a branch of GlaxoSmithKline plc, disclosed that it received approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for Vocabria (cabotegravir injection and tablets). This approval is for its combination with Janssen Pharmaceutical Companies' Rekambys and Edurant from Johnson & Johnson, marking the initial and exclusive comprehensive long-acting treatment for HIV in Japan.
The upsurge in research and development activities in drug discovery is predicted to boost the market growth during the forecast period. This involves the exploration of novel drug targets, the undertaking of clinical trials, and the examination of combination therapies. For instance, in February 2023, Merck, also recognized as MSD outside the United States and Canada, has declared the initiation of enrollment in its latest Phase 3 clinical initiative. This program involves the investigation of the investigational once-daily islatravir 0.25 mg in conjunction with doravirine 100 mg (DOR/ISL) for treating HIV-1 infection.
By medication class, multi-class combination drugs was the highest revenue-grossing segment in the global HIV drugs market in 2023 owing to the widespread utilization of combination drugs encompassing multiple classes in HIV treatment, the efficacy of these multi-class combinations against HIV, and the increasing endorsement of such combination drugs. For instance, in December 2022, Gilead Sciences, Inc. reported that the U.S. Food and Drug Administration (FDA) has approved Sunlenca (lenacapavir) in combination with other antiretroviral(s) (ARV) for treating HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. Additionally, HIV integrase strand transfer inhibitors is predicted to grow at fastest CAGR during the forecast period as it is recommended as primary treatment for HIV and the continuous introduction of new drugs, this combination represents a significant advancement in HIV therapy.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global HIV drugs market in 2023 owing to the substantial drug sales originating from hospital pharmacies, the elevated count of HIV patients seeking treatment at hospital facilities, and surge in market approvals by regulatory bodies. For instance, in February 2023, ViiV Healthcare, a subsidiary of GlaxoSmithKline plc, declared that the European Commission has approved Marketing Authorization for Triumeq. This approval pertains to a dispersible tablet version of the fixed-dose combination of abacavir, dolutegravir, and lamivudine, designed for treating pediatric patients weighing between 14 kg to 25 kg with human immunodeficiency virus type 1 (HIV-1). Additionally, online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the ease of shopping, growth in online sales, advancements in logistics, and simplified payment choices contribute to the accessibility and substantial discounts and offers offered by these digital platforms.
North America region is anticipated for the highest revenue share during the forecast period owing to the increase in the quantity of clinical trials for HIV medications, the presence of advanced healthcare facilities, substantial healthcare funding from governmental entities, the presence of an intricate reimbursement system designed to lower expenditure, and the rising number of approvals from regulatory bodies. For instance, in March 2022, Janssen Pharmaceutical, a fully owned subsidiary of Johnson & Johnson, reported that the U.S. Food and Drug Administration (FDA) granted approval for CABENUVA (cabotegravir and rilpivirine) to treat HIV-1 in adolescents who have achieved virological suppression. Developed in collaboration with ViiV Healthcare, CABENUVA stands as the initial and sole comprehensive long-acting treatment regimen for HIV-1. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the existence of major contributors, an upswing in research and development endeavors focused on HIV medications, an increase in the demand for HIV drugs, a growing population coupled with extended life expectancy, and an uptick in regulatory approvals for innovative products. For instance, in May 2022, ViiV Healthcare, a branch of GlaxoSmithKline plc, disclosed that it received approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for Vocabria (cabotegravir injection and tablets). This approval is for its combination with Janssen Pharmaceutical Companies' Rekambys and Edurant from Johnson & Johnson, marking the initial and exclusive comprehensive long-acting treatment for HIV in Japan.
Segmentation: HIV Drugs Market Report 2023 - 2034
HIV Drugs Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Entry Inhibitors
- Selzentry
- Fuzeon
- Rukobia
- Multi-Class Combination Drugs
- Atripla
- Complera
- Prezcobix
- Stribild
- Genvoya
- Odefsey
- Symtuza
- Triumeq
- Descovy
- Dovato
- Others
- Protease Inhibitors (PIS)
- Aptivus
- Kaletra
- Lexiva/ Telzir
- Norvir
- Viracept
- Others
- Nucleoside Reverse Transcriptase Inhibitors (NRTIS)
- Emtriva
- Epivir
- Epzicom
- Truvada
- Biktavry
- Others
- HIV Integrase Strand Transfer Inhibitors
- Isentress
- Tivicay
- Apretude
- Juluca
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS)
- Edurant
- Others
- Others
HIV Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Drugs Stores & Retail Pharmacies
- Online Pharmacies
HIV Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. HIV Drugs Market: Drug Class Estimates & Trend Analysis
8. HIV Drugs Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America HIV Drugs Market
11. Europe Global HIV Drugs Market
12. Asia Pacific Global HIV Drugs Market
13. Latin America Global HIV Drugs Market
14. MEA Global HIV Drugs Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences Inc.
- Merck & Co. Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd.
- Johnson & Johnson
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 34.26 Billion |
| Forecasted Market Value ( USD | $ 64.83 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
